Cpg-dna Therapy
Cpg-dna Therapy - Related Videos
13:21
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
0 Views •
Cited by 2 •
2017
This work describes an optimized methyl-CpG-binding domain (MBD) sequencing protocol and a computational pipeline to identify differentially methylated CpG-rich regions in chronic lymphocytic leukemia (CLL) patients.
08:40
Methyl-binding DNA capture Sequencing for Patient Tissues
0 Views •
Cited by 1 •
2016
Here we present a protocol to investigate genome wide DNA methylation in large scale clinical patient screening studies using the Methyl-Binding DNA Capture sequencing (MBDCap-seq or MBD-seq) technology and the subsequent bioinformatics analysis pipeline.
08:47
DNA Methylation Analysis
0 Views •
2023
Methylation at CpG dinucleotides is a chemical modification of DNA hypothesized to play important roles in regulating gene expression. In particular, the methylation of clusters of methylation sites, called “CpG islands”, near promoters and other gene regulatory elements may contribute to the stable silencing of genes, for example, during epigenetic processes such as genomic imprinting and X-chromosome inactivation. At the same time, aberrant CpG methylation has been shown to be associated with...
12:34
DNA Methylation: Bisulphite Modification and Analysis
0 Views •
Cited by 75 •
2011
The gold standard for DNA methylation analysis is genomic sequencing of bisulphite converted DNA. This method takes advantage of the increased sensitivity of cytosine compared with 5-methylcytosine (5-MeC) to bisulphite deamination under acidic conditions. Unmethylated cytosines can be distinguished from methylated cytosines after PCR amplification of the target genomic DNA.
08:38
Targeted DNA Methylation Analysis by Next-generation Sequencing
0 Views •
Cited by 83 •
2015
Bisulfite amplicon sequencing (BSAS) is a method for quantifying cytosine methylation in targeted genomic regions of interest. This method uses bisulfite conversion paired with PCR amplification of target regions prior to next-generation sequencing to produce absolute quantitation of DNA methylation at a base-specific level.
FAQs
Unmethylated CpG motifs provide the immune-recognition feature that makes the DNA resemble microbial genetic material. When immune cells detect these motifs through Toll-like receptor 9, they initiate signaling rather than simply encountering DNA as an inert substance. This recognition helps determine how strongly the treatment can stimulate innate defenses and support antigen-specific adaptive responses.
Toll-like receptor 9 serves as the key immune-sensing component for CpG motifs. Its activation triggers signaling inside immune cells, which can increase innate immune activity and contribute to adaptive immune responses directed toward an antigen. This receptor therefore connects motif recognition with the downstream immunomodulatory effects being investigated in medical applications.
The initial response is associated with enhanced innate immune activity, providing a broad defense-oriented effect. At the same time, CpG-DNA therapy can support antigen-specific adaptive responses, which are directed toward a defined antigen rather than acting broadly. This combination makes the approach relevant to both general immune stimulation and vaccine-related immune development.
The treatment's potential impact depends not only on immune stimulation but also on reaching appropriate target tissues and limiting unwanted inflammation. Delivery can influence where the DNA acts, while control of activation can affect whether the response remains useful or becomes excessive. These factors are therefore central to developing a balanced therapeutic strategy.
As a vaccine adjuvant, CpG-DNA therapy can strengthen the immune environment surrounding vaccination and support antigen-specific adaptive responses. Its role is to enhance the immunological effect associated with the vaccine rather than replace the antigen. This application is being investigated because the same CpG-driven signaling that activates innate defenses may help improve adaptive response development.
Investigated applications include vaccine adjuvant use, cancer treatment strategies, infection-related treatment strategies, and other conditions involving immune regulation. These settings differ in their therapeutic goals, but each depends on directing immune activity toward a useful outcome. The approach remains especially relevant where immune stimulation or immune-response control could influence disease management.
Evaluation should consider whether the treatment enhances innate immune activity, supports an antigen-specific adaptive response, reaches the intended tissue, and avoids unwanted inflammation. These outcomes reflect both efficacy and immune control. A promising response therefore requires more than activation alone; it must also demonstrate appropriate targeting and regulation for the medical setting being studied.